The Jacobi Burn Center from New York presented a compelling case series at the 2025 American Burn Association (ABA) Annual Meeting in Phoenix, AZ, showcasing improved hemostasis and wound healing results in burn wound management using BloodSTOP iX, an Etherified Carboxymethyl Cellulose (eCMC) matrix. BloodSTOP iX is one of the flagship medical technologies manufactured by LifeScience PLUS, Inc.
The poster, titled “Etherified Carboxymethyl Cellulose Matrix for Optimizing Hemostasis and Enhancing Graft Healing: A Case Series”, shared outcomes from five patients undergoing split-thickness skin grafting. The eCMC matrices were used intraoperatively to control bleeding at graft sites and donor sites, demonstrating consistent, immediate hemostasis and contributing to an average re-epithelialization time of just 7 to 10 days.
“There’s zero clot—that’s something that has been great about [BloodSTOP iX]. We don’t have issues with clots accumulating and making the graft fail,” said Dr. Maria Barahona of the Jacobi Burn Center during her presentation.
She added, “One of the first patients that really sold me on it was a feet burn. We put the BloodSTOP [iX], then the skin graft—and he healed as if nothing happened. No scar, nothing.”
According to the Jacobi team, the use of eCMC contributed to rapid hemostasis, decreased blood loss, enhanced tissue regeneration, reduced incidence of hypertrophic scarring, and excellent cosmetic and functional outcomes—especially critical in high-risk areas such as the hands and feet.
LifeScience PLUS is honored to see eCMC featured in cutting-edge clinical practice, and remains committed to supporting medical teams with its total solution technology: safe, effective and fast matrix dressings for both hemostasis and wound healing.